News & SEC Filings

View the latest news and SEC filings

News

RAHWAY, N.J. & RALEIGH, N.C.–( BUSINESS WIRE )– Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, today announced that the companies have entered into a

LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will participate in fireside chats at the following conferences in June 2025: Jefferies Global Healthcare Conference Date: Wednesday, June

Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dual inhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., May 06, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a biopharmaceutical company focused on

Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre ® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m.

SEC Filings

Date Form Filing Group

May 7, 2019

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

6-K

Current Reports

May 3, 2019

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

6-K

Current Reports

April 12, 2019

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

6-K

Current Reports

April 2, 2019

Filing by person(s) reporting owned shares of common stock in a public company >5%

SC 13D

Other

March 26, 2019

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

6-K

Current Reports

March 26, 2019

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

6-K

Current Reports

March 19, 2019

Registration of securities of foreign private issuers pursuant to section 12(b) or (g)

20-F

Annual Filings

March 12, 2019

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

6-K

Current Reports

February 28, 2019

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

6-K

Current Reports

Developing novel therapeutics for respiratory diseases

Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.

Close up of female doctor hold woman patient hands help on personal therapy session, psychologist or counselor show understanding and care, support depressed suffering client on treatment